Articles related to Family Medicine/General Practice

Findings: Primary outcomes included AMI, HF, stroke, and CVEs; 51 secondary and safety outcomes included angioedema, cough, syncope, and electrolyte abnormalities. ACE inhibitors were associated with a significantly increased risk of four secondary and safety outcomes compared with ARBs.Design: Multinational cohort study; Patients: ~2.3M ACE, ~674K ARB 

The additional approval expands immunization coverage to the most at-risk group for acquiring shingles – the immunocompromised. It also shortens the time to the second dose in the 2-dose Shingrix schedule.  Decision support based on the Zoster Efficacy Study in Patients Undergoing HSCT (ZOE-HSCT) phase III trial (JAMA).

According to the SUSTAIN FORTE study presented online in The Lancet Diabetes & Endocrinology, doubling the dose of semaglutide (Ozempic) might be a helpful option for people not achieving glycemic goals. Still, some researchers aren’t convinced this is a sound strategy – “statistically significant but barely clinically relevant” — suggesting opting for another agent when faced with a patient struggling to control HbA1c.

According to the interim guidance, “remote-learning highlighted inequities in education, was detrimental to the educational attainment of students of all ages, and exacerbated the mental health crisis among children and adolescents.” The AAP continues to recommend that all staff and students who are 2 years or older wear face masks unless medical or developmental conditions prohibit their use, urging everyone who is eligible to get vaccinated against COVID-19.

In this KevinMD.com podcast/article, the nurse practitioner sums up their current feelings in the last words of the piece: “If I leave now, I still deal with this for months, plus all of my patient’s grief and feelings of betrayal. If I stay, maybe it will get better. It could hardly get worse. But in the end, I don’t want to lose myself either, and at some point, there has to be a line that is too far. It is just hard to know what that is anymore.”

In a study in the journal Nature Cancer, the researchers found that in laboratory cell lines and tumor models novobiocin selectively killed tumor cells with abnormal BRCA1 or BRCA2 genes, which help repair damaged DNA. The drug, developed in the 1950s and largely supplanted by newer drugs, was effective even in tumors resistant to agents known as PARP inhibitors, which have become a prime therapy for cancers with DNA-repair glitches.